

Application of: Ronald A. FLEMING *et al.*

Confirmation No.: 7276

Application No.: 10/783,927

Art Unit: 1614

Filed: February 20, 2004

Examiner: James D. Anderson

For: Phospholipids for the Treatment of
Infection by Togavirus, Herpes Viruses
and Coronaviruses

Attorney Docket No.: 066438-5001
(Formerly *Kucera-5001*)

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97**

Commissioner for Patents
U.S. Patent and Trademark Office
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to References A1-A27, B1-B13, and C1-C35, cited on the attached Substitute for form 1449/PTO.

Identification of the listed reference is not to be construed as an admission of Applicants or Attorneys for Applicants that the references are available as "prior art" against the subject application.


Applicants respectfully request that the Examiner review these references and make them of record in the present application by signing and returning the enclosed List of References Cited.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits therefore no fee is required.

U.S. Application No.: 10/783,927
Attorney Docket No. 066438-5001

Should the Patent Office determine that any fees are due, please charge the additional fees to Morgan, Lewis & Bockius LLP Deposit Account 50-0310.

Respectfully submitted,



Dean L. Fanelli
Reg. No. 48,907

Date: September 14, 2007

MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 739-3000-phone
(202) 739-3001-fax
Customer No.: 009629